Deutsche Bank Ag\ Viridian Therapeutics, Inc.\De Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Deutsche Bank Ag\ holds 379,547 shares of VRDN stock, worth $7.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

379,547

Previous 48,445 683.46%

Holding current value

$7.51 Million

Previous $630,000 1270.48%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$12.16 - $23.33 $4.03 Million - $7.72 Million	331,102 Added 683.46%	379,547 $8.63 Million
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.26 $19,395 - $28,858	1,672 Added 3.57%	48,445 $630,000
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $68,052 - $94,851	3,982 Added 9.31%	46,773 $818,000
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $230,940 - $467,280	20,768 Added 94.3%	42,791 $931,000
Q3 2023 Nov 09, 2023	SELL	$15.16 - $24.7 $1.07 Million - $1.74 Million	-70,631 Reduced 76.23%	22,023 $337,000
Q2 2023 Aug 14, 2023	SELL	$22.57 - $29.67 $3.64 Million - $4.79 Million	-161,460 Reduced 63.54%	92,654 $2.2 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $5.94 Million - $8.91 Million	237,028 Added 1387.26%	254,114 $6.46 Million
Q4 2022 Feb 13, 2023	BUY	$18.78 - $29.74 $112,773 - $178,588	6,005 Added 54.19%	17,086 $499,000
Q3 2022 Nov 14, 2022	SELL	$10.7 - $25.5 $18,050 - $43,018	-1,687 Reduced 13.21%	11,081 $227,000
Q2 2022 Aug 11, 2022	BUY	$9.55 - $19.0 $121,934 - $242,592	12,768 New	12,768 $148,000

Others Institutions Holding VRDN

# of Institutions

179

Shares Held

76.8M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $789M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account